- Home
- TNYA
as 01-14-2025 4:00pm EST
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 119.2M | IPO Year: | 2021 |
| Target Price: | $17.33 | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.99 - $7.01 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tenaya Therapeutics Inc. (TNYA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Saito Chihiro | TNYA | SVP, Accounting and Fin. Ops. | Nov 18 '24 | Sell | $2.12 | 2,258 | $4,786.96 | 60,983 |
Latest Tenaya Therapeutics Inc. News
TNYA Breaking Stock News: Dive into TNYA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
MT Newswires
a month ago
Update: Tenaya Shares Sink After Readout of Heart Disease Therapy Shows Manageable Safety Profile
MT Newswires
a month ago
Leerink Partners Adjusts Tenaya Therapeutics Price Target to $6 From $8, Maintains Outperform Rating
MT Newswires
a month ago
Tenaya Says TN-201 Gene Therapy Well Tolerated in Initial Hypertrophic Cardiomyopathy Trial Patients
GlobeNewswire
a month ago
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
GlobeNewswire
a month ago
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
GlobeNewswire
2 months ago
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
GlobeNewswire
2 months ago
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Compare TNYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNYA Tenaya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.